JAMA study finds mifepristone mail dispensing had no increase in adverse outcomes

The Journal of the American Medical Association publishes a study analyzing adverse outcomes from mifepristone dispensed by mail between 2021 and 2025, finding no statistically notable increase in complications compared to in-person dispensing. The study uses data from 180,000 patients across 14 states that allowed mail dispensing after the 2021 FDA policy change. The findings directly undercut the Fifth Circuit's ruling, which relies in part on the premise that the FDA failed to adequately study safety risks before lifting in-person requirements. The study becomes a main piece of evidence in the expected Supreme Court challenge to the Fifth Circuit decision, with physicians and public health organizations citing it to argue the in-person requirement has no clinical basis.